This interest is fueled by post mortem and in vivo studies, including fluid biomarkers and PET imaging, which consistently show a relationship between tau pathology and cognitive impairment in the AD clinical spectrum.44, 45, 46. Here, MAPT is linked to Cognitive impairment.